NYSE:JNJPharmaceuticals
How Investors Are Reacting To Johnson & Johnson (JNJ) Oncology And Rare-Disease Trial Wins
In mid-June 2026, Johnson & Johnson reported strong Phase 3 MonumenTAL-3 data for TALVEY in relapsed/refractory multiple myeloma and positive Phase 2/3 ENERGY results for IMAAVY in warm autoimmune hemolytic anemia, supporting an FDA Priority Review for a new indication.
These late-stage successes highlight Johnson & Johnson’s ability to advance first-in-class mechanisms like GPRC5D bispecifics and FcRn inhibition into areas of high unmet medical need, potentially broadening its Innovative...